Aspire Biopharma Holdings Inc (ASBP)

$0.61 +0.03 (4.64%)
Market Cap 4.52M
Revenue (ttm) 0.00
Net Income (ttm) -359,071.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 61,900
Avg Vol 548,178
Day's Range N/A - N/A
Shares Out 7.77M
Stochastic %K 38%
Beta 0.38
Analysts Strong Buy
Price Target N/A

Latest News on ASBP

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Mar 20, 2025, 8:30 AM EDT - 13 days ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Mar 13, 2025, 8:30 AM EDT - 20 days ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Mar 11, 2025, 8:00 AM EDT - 22 days ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Mar 3, 2025, 7:30 AM EST - 4 weeks ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Feb 25, 2025, 7:30 AM EST - 5 weeks ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Feb 20, 2025, 6:15 PM EST - 5 weeks ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement